Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pharmaceutical Eli Lilly’s Omvoh Gains CHMP Nod for Crohn’s Disease Treatment
chrons

Eli Lilly’s Omvoh Gains CHMP Nod for Crohn’s Disease Treatment

19th December 2024

 Eli Lilly has achieved a significant milestone as the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended Omvoh (mirikizumab) for adults with moderately to severely active Crohn’s disease. This endorsement is pivotal for patients who haven’t found success with other treatments, bolstering Eli Lilly’s position in the inflammatory bowel disease (IBD) market.

Crohn’s disease, a severe inflammatory bowel condition, affects millions worldwide, leading to severe symptoms like persistent diarrhea and abdominal pain. Omvoh, previously approved in the EU for ulcerative colitis — another form of IBD — targets interleukin-23, reducing inflammation and alleviating symptoms. The CHMP’s decision was underpinned by promising results from the VIVID-1 trial, which demonstrated clear efficacy and safety, with Omvoh-treated patients showing improved endoscopic response and clinical remission at 12 and 52 weeks.

Omvoh’s potential in enhancing bowel urgency severity through a Lilly-developed scale further emphasises its benefits. Mark Genovese of Lilly highlighted how Omvoh could transform patient experiences by addressing disruptive Crohn’s symptoms.

As the European Commission deliberates the CHMP’s recommendation, Omvoh stands at the brink of expanding its impact in the IBD field. This progresses Eli Lilly’s mission to revolutionise treatments for patients globally, offering renewed hope for those battling the challenging symptoms of Crohn’s disease.

Contact Marcus for more details.

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.